In this issue:
GLP-1 agonists: kidney and CV disease outcomes
CGM metrics and hypoglycaemia duration with icodec vs. glargine in type 2 diabetes
Insulin efsitora vs. degludec in type 2 diabetes
Diabetes prevalence and treatment trends: 1990–2022
Postprandial hypoglycaemia after gastric bypass in type 2 diabetes
ASB/SSB consumption, physical activity and type 2 diabetes risk
Autoimmune diseases and LADA
Contribution of infection to mortality in type 2 diabetes
Infection risk according to type 2 diabetes subgroup
Oral glucose-lowering agents vs.insulin for gestational diabetes
Please login below to download this issue (PDF)